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Highlevelsofproﬁbrinogeniccytokinetransformingfactorbeta(TGF-β),metalloprotease(MMP2),andtissueinhibitorofmatrix
metalloprotease 1 (TIMP1) contribute to ﬁbrogenesis in hepatitis C virus (HCV) infection and in alcohol-induced liver disease
(ALD). The aim of our study was to correlate noninvasive serum markers in ALD and HCV patients with various degrees of
inﬂammationandﬁbrosisintheirbiopsies.Methods.SerumcytokineslevelsinHCV-infectedindividualsinthepresenceorabsence
of ALD were measured. Student’s-t-test with Bonferroni correction determined the signiﬁcance between the groups. Results.B o t h
tumor-necrosis-factor- (TNF)-α and TGF-β levels increased signiﬁcantly with the severity of inﬂammation and ﬁbrosis. TGF-β
levels increased signiﬁcantly in ALD patients versus the HCV patients. Proinﬂammatory cytokines’ responses to viral and/or toxic
injury diﬀered with the severity of liver inﬂammation. A combination of these markers was useful in predicting and diagnosing
the stages of inﬂammation and ﬁbrosis in HCV and ALD. Conclusion. Therapeutic monitoring of TGF-β and metalloproteases
provides important insights into ﬁbrosis.
1.Introduction
Alcohol-induced liver disease (ALD) encompasses a spec-
trum of hepatic injury, ranging from simple steatosis to
cirrhosis. Alcohol ethylic (ethanol), a hepatotoxin, produces
the oldest form of liver injury known to humankind [1–4].
In addition, ethanol-inducible cytochrome P-450 (CYP2E1)
increases vulnerability of the heavy drinker to commonly
prescribed drugs [5–7]. Moreover, dysregulated cytokines,
including TNF-α and downstream cytokines, play a pivotal
role in the pathophysiology of ALD [8, 9]. In addition,
Th1 cells produce interleukin (IL)-2, interferon (IFN)-γ,
and TNF-α, that promote inﬂammation and cell-mediated
immunity in an attempt to control infection [10–12]. Th22 International Journal of Hepatology
cells produce IL-10 [10] and IL-4, inducing ﬁbrogenesis
[13–17]. In HCV, an impaired HCV-speciﬁc CD4+ T-cell
response can lead to persistence of the virus characterized
by inﬂammation [18–22]. The expression of suppressor of
cytokinesignaling(SOCS)proteinspermitsthehosttobetter
respond to therapies [23].
The initial liver histological changes are characterized by
accumulation of inﬂammatory cells and matrix deposition
around the portal vein [24–26]. In liver disease, including
ALD and HCV, liver ﬁbrosis is deﬁned as the abnormal accu-
mulation of extracellular matrix (ECM) [26–33]. In all cases,
inﬂammation plays a crucial role [24, 34]. TGF-β mediates
the eﬀects through signal mothers against decapentaplegic
(Smad) proteins [35, 36].
In response to liver injury neutrophils migrate to
the site of infection through chemokines. Distinct pat-
terns of expression of each chemokine were noted on
Kupﬀer cells (IL-8) (CXC) [4, 36], sinusoidal endothelial
cells macrophage inﬂammatory protein 1 (MIP-1) (CC)
[37], hepatocytes (CXC chemokines, IL-8) [38], lympho-
cytes (MIP-1), (CX3C) [39], hepatic stellate cells (HSCs)
{monocyte chemoattractant protein 1 (MCP-1) [40–42],
regulated upon activation of normal T-cell expressed and
presumably secreted (RANTES) (CC)} [42]. Other biomark-
ersthatareattributedtoHSCactivityincludelevelsofTIMPs
[43, 44]. MMP-1 levels, on the other hand, signiﬁcantly
decreased during ﬁbrogenesis [45]. Alcohol consumption in
HCV-infected people is known to cause accelerated progres-
sion of liver ﬁbrosis, a higher frequency of cirrhosis, and an
increased incidence of HCC [46–48]. Genes associated with
ﬁbrosis/cell adhesion/ECM were not speciﬁc to alcohol and
have been reported in HCV-induced liver cirrhosis [49].
Previously,wereportedthatseralevelsofRANTES,TNF-
α, IL-6, IL-8, and IL-12 as well as TGF-β in HCV-infected
individuals are higher as compared to healthy controls [34].
A strong correlation was observed between the degree of
inﬂammation, as shown by the histological activity index,
and TNF-α levels, thus indicating the possibility of using
TNF-α levels as a marker of the degree of liver inﬂammation.
Furthermore, TGF-β levels were signiﬁcantly higher among
those with moderate and mild ﬁbrosis (F2-F3) regardless
of the inﬂammation, suggesting the role TGF-β in HCV
patients takes place mostly in earlier stages of the disease
before cirrhosis is well established [34].
Theaimofourpresentstudywastocorrelatenoninvasive
serum markers: cytokines, chemokines in ALD, and chronic
HCV patients with various degrees of inﬂammation and
ﬁbrosis in their biopsies.
2. Methods
2.1. Patients. We studied 260 AH:140 (mild histological
activity index (HAI), 60, high HAI, and 60 cirrhotics; AH,
comorbidity, 60 HCV (30 cirrhotics). From 1180 HCV (that
declared not drinking):170—low ﬁbrosis—HAI; 450—mild
ﬁbrosis—low HAI; 440—moderate ﬁbrosis—HAI; 120—
high ﬁbrosis—high HAI. ALD was considered as resulting
from long-term heavy drinking (over 80mg/alcohol/day).
The patient population was 98% Caucasian, treated in
Canada, France, and Israel.
2.1.1. Chemical Measurements. The laboratory services at
each of the participating sites performed routine blood tests
including alanine aminotransferase (ALT), aspartate amino
transferase (AST), bilirubin, albumin, and platelet counts.
2.1.2. Liver Biopsy. After submitting an informed consent
document, all patients underwent a percutaneous liver
biopsy to ascertain the diagnosis and their stage of liver
injury.Biopsyspecimenswereﬁxed,paraﬃn-embedded,and
stained with haematoxylin and eosin, Masson’s trichrome,
and Sirius red. All specimens were examined and graded
by the pathologists of the speciﬁc medical center. A ﬁbrosis
score from 0 to 4 and an inﬂammatory score from 0 to
16 were adopted according to the severity and the extent
of damage. Liver ﬁbrosis was evaluated according to the
METAVIR scoring system. Fibrosis (F) was staged on a scale
of 0 to 4: F0, no ﬁbrosis; F1, portal ﬁbrosis without septa; F2,
fewsepta;F3,numerousseptawithoutcirrhosis;F4,cirrhosis
[32].
2.1.3. Inclusion/Exclusion Criteria. Each treating physician
established a diagnosis based upon the following criteria:
clinical presentation, a history of excessive alcohol con-
sumption, and exclusion of other etiology, elevated liver
transaminases, neutrophil counts, serum bilirubin, and
impaired coagulation. In addition, diagnosis was reached
using appropriate virological and histological criteria.
HCV-infected patients tested positive for antibody to
HCV on third-generation enzyme-linked immunosorbent-
assay (ELISA) or recombinant immunoblot assay (Abbott
Laboratories, Chicago, IL, USA). After that the viral load was
measured. The patients had persistently elevated serum ALT
levels for more than 6 months and no evidence of infection
with hepatitis B virus (absence of detectable hepatitis B
surface antigen). Additionally, there was no presence of
antihuman immunodeﬁciency virus antibodies. Also other
causes of chronic liver disease (hepatotoxic drugs, autoim-
mune chronic hepatitis, hemochromatosis, Wilson’s disease,
and -1 antitrypsin deﬁciency) and a history of decom-
pensated cirrhosis (ascites, bleeding esophageal varices, or
hepatic encephalopathy) were excluded. Moreover, none of
these patients had received immunomodulatory or antiviral
therapy. Liver histology showed lesions characteristic of
chronic hepatitis.
All the patients described in the study had been treated
for their disease in the speciﬁc medical facility in his (her)
own country. The Ethics Committees of the speciﬁc Medical
Centre approved this study, which is in concordance with
the ethical guidelines of the 1975 Declaration of Helsinki
forresearchinvolvinghumanparticipants.Informedconsent
was obtained from all participating patients.
2.1.4. Characteristics Studied. The following characteristics
were compared between the groups: sex, age, duration of
HCV infection, or alcohol use (80g or more/day for at leastInternational Journal of Hepatology 3
Table 1: Baseline characteristics ALD patients.
Characteristics F2 (n = 140) F3 (n = 60) F4 (n = 60)
Age (years) 27 ± 84 6 ± 12 64 ± 5∗
Sex (F/M) 24/116 8/52 0/60
Alcohol consumption (years) 10 ± 42 0 ± 62 8 ± 16
ALT (U/L) 46.0 ±3.06 5 .0 ± 11.0∗∗ 57.0 ±12.0∗∗
AST (U/L) 45.5 ±4.58 0 .5 ± 15.0∗∗ 77.0 ±10.0∗∗
Bilirubin (mg/dL) 1.2 ±0.51 .96 ±1.20 5.80 ±1.50
Values represent mean ± S.D. ∗P<0.05 higher than F2 and F3; ∗∗P<0.001 higher, when compared to F2.
Table 2: Baseline characteristics: HCV-infected individuals.
Characteristics F0-F1 (n = 170) F2 (n = 450) F3 (n = 440) F4 (n = 120)
Age (years) 39 ± 16 47 ± 64 6 ± 75 4 ± 10∗
Sex (F/M) 48/122 177/273 132/308 50/70
HCV infection (years) 15 ± 61 8 ± 72 2 ± 82 7 ± 12
ALT (U/L) 70.0 ±20.07 9 .0 ±10.09 9 .0 ±5.0∗∗ 86.0 ±20.0
AST (U/L) 32.0 ± 4.04 2 .0 ±8.04 0 .5 ± 15.05 0 .8 ±5.0
Bilirubin (mg/dL) 0.26 ± 0.53 .6 ±2.55 .5 ±3.50 8.5 ±5.5
Values represent means ± S.D; ∗P<0.05 higher when compared to F0-F1, F2, and F3; ∗∗P<0.001 higher when compared to F0 or F2.
1 year), liver histology, HCV genotype, and viral load. Tables
1, 2,a n d3 record the characteristics of the patients studied.
2.1.5. Laboratory Methods. We measured serum: IL-6, IL-
8, TNF-α,T G F - β, RANTES, Fas-ligand (FAS-L), hyaluronic
acid (HA), TIMP, and apoptosome (M30). We also per-
formedthecorrelationbetweenthesecytokines,chemokines,
and apoptosis markers with the degree of inﬂammation and
ﬁbrosis as shown by light microscopy (LM) as well as with
other biochemical parameters such as ALT, AST, bilirubin,
albumin, ferritin as well as HCV genotype, and viral load.
Patient serum specimens were kept at 4◦C immediately after
collection, centrifuged, aliquoted for each measurement, and
frozen at −80◦C within 2h of being drawn. This provides
the optimal conditions for reliable results [11]. Cytoscreen
Immunoassay kits (BioSource International, Camarillo, CA,
USA) for human IL-6, IL-8, TNF-α,T G F - β,R A N T E S ,
TIMP quantiﬁed the cytokines as described previously
[23].
2.2. Fas/sFasL Measurements. Cytoscreen, Immunoassay
Kits, Human Fas (BioSource International, Camarillo, CA,
USA), and soluble FasL (Bender MedSystems, Vienna,
Austria) were used for the quantitative determination of
Fas/sFasL in serum as previously described [50]. The cor-
relation coeﬃcient was linear (Fas r = 0.996; FasL r =
0.998) in a concentration range between 0.23 and 15ng/mL
for Fas and between 0.16 and 10ng/mL for FasL. The
samples having higher concentrations were diluted. Each
specimen was analyzed in triplicate with a sensitivity and
speciﬁcity of 96% and 92%, respectively. We used standards
and reference reagents available from the National Institute
for Biological Standards and Controls (NIBSC, Herts., UK).
These methods are standardized in our laboratory according
to the procedures described [11, 50, 51].
2.3. Apoptosis Measurements. Apoptosis was measured using
the M30-Apoptosense ELISA (Bender MedSystems, Vienna,
Austria) using the manufacturer instruction. It is a solid-
phase, two-site immunosorbent assay. The absorbance was
measured in a microplate reader at 450nm. The corre-
lation coeﬃcient was linear (r = 0.995) in a concen-
tration range between 50 and 1000 U/mL. The samples
having higher concentrations were diluted. Each speci-
men was analyzed in triplicate with a sensitivity of 95%
and speciﬁcity of 90%. We used standards and refer-
ence reagents available from Bender MedSystems (Vienna
Austria).
2.4. Detection of Serum Hepatitis C Virus RNA. For quan-
titation of HCV RNA in human we used “AMPLICOR
HCV MONITOR test (Roche Diagnostic, PQ, Canada and
Neuilly, France)”. The test is specially designed for assessing
viral load with the low linear sensitivity 6 × 102.T h e
p r o c e d u r ei sb a s e do nﬁ v em a j o rs t e p sr e q u i r e db yt h e
specimen preparation, reverse transcription of target RNA to
generate complementary DNA (cDNA), PCR ampliﬁcation
of target cDNA using HCV-speciﬁc complementary primers,
hybridization of the ampliﬁed DNA to oligonucleotide
probes speciﬁc to the target, and detection of the probe
bind ampliﬁer. In 100 patients we have evaluated the
performance of newly developed automated real-time PCR
assay, the COBAS Ampliprep/COBAS TaqMan (CAP/CTM)
with AMPLICOR HCV MONITOR test (Roche Diagnostic,
PQ, Canada) COBAS as previously described [52]. The
overall concordance for negative/positive results was 100%
for HCV. All assays were equally able to quantify HCV in
genotype 1. The results indicate that the real-time PCR
assay covers better viral dynamic. Serum HCV RNA detec-
tion and HCV genotyping were performed for diagnostic
purposes.4 International Journal of Hepatology
Table 3: Baseline characteristics ALD infected with HCV.
Characteristics F2 (n = 10) F3 (n = 40) F4 (n = 30)
Age (years) 50 ± 15 66 ± 27 64 ± 32
Sex (F/M) 0/10 2/38 5/25
HCV infection (years) 22 ± 72 5 ± 15 35 ± 25
ALT (U/L) 34.5 ±10.56 0 .5 ±14.0∗ 126.0 ±42.0∗∗
AST (U/L) 70.0 ±25.0 154.0 ±45.0 250.0 ±75.0
Bilirubin (mg/dL) 0.36 ±0.55 .5 ±2.50 12.80 ±8.00
Values represent means ± S.D; ∗P<0.05 higher when compared to F2; ∗∗P<0.001 higher when compared to F2 or F3.
2.5. Genotyping of Hepatitis C Virus. HCV genotyping was
performed at initiation of treatment in the 5  untranslated
region of the HCV genome, using reverse hybridization with
the line probe assay (InGeN, Rungis, France). The HCV
line-probe assay contains 15 probe lines, allowing identiﬁ-
cation of HCV types 1 to 5 as well as their subtypes a and b
[23].
2.6. Statistical Analysis. We calculated the statistical signiﬁ-
cance of parameters by using SPSS 9.0 for windows (SPSS
Inc.,Chicago,Illinois,USA).Normalityofthedatawastested
by means of Shapiro and Wilk’s W-test. Most of the data
was in a normal distribution. All statistical signiﬁcance was
assessed at the 0.05 levels. Baseline data were descriptively
summarized. To test diﬀerences between groups, we com-
pared mean and standard deviation (S.D.) of each parameter
using either parametric or nonparametric tests. Diﬀerences
among groups were determined by the use of conﬁdence
intervals and analysis of variance. The 2 test or Fisher’s
exact test was used to compare frequency data between
groups. The initial histological lesions were evaluated by
the non-parametric rank correlation for each parameter.
Mann-Whitney and Wilcoxon rank-sum tests were used
to compare values of continuous variables. Correlations
between variables were analyzed calculating the Spearman
rank correlation coeﬃcient. To determine the independent
prognostic value of the selected characteristics, a logistic
regression model was used.
3. Results
3.1. Patient Characteristics. Baseline demographics and dis-
e a s ec h a r a c t e r i s t i c sw e r ec o m p a r a b l ea c r o s sg r o u p s( H C V .
HCV-ALD, and ALD), as shown in Tables 1, 2,a n d3,
conﬁrmed by the Kruskal-Wallis test. All subjects had
clinically compensated but active liver disease based on
evaluations of liver biopsies and ALT and AST levels. A num-
ber of laboratory abnormalities, including elevated serum
aminotransferases, were seen in patients with alcoholic liver
injury, in the presence or absence of HCV. In Tables 1 and 3
we reported a speciﬁc feature used to diagnose ALD patients:
the AST/ALT ratio which was higher than 1.2. Ratios of
AST/ALT greater than 1 are considered suggestive of alcohol-
induced etiology.
Serum AST/ALT was typically elevated 1.2–2 times in
ALDindividualsaswellasinHCV-ALDpatients.Inalcoholic
hepatitis, the levels of AST and ALT were 2–6 times higher
than the upper limits of normal levels in healthy individuals.
Table 2 presents the characteristic analysis of HCV-
patients. Consistent with previous studies and with patient
populations in Europe and North America, the majority of
HCV-subjects had genotype 1 and 98% of all the patients
were Caucasians.
The viral load was not signiﬁcantly diﬀerent between the
HCV (7.3 ±6.4× 106) and ALD-HCV (6.8 ± 5.8× 106).
In patients with mild ﬁbrosis (F3), there was a dramatic
increase in the HAI score as compared to those with
moderate ﬁbrosis (F2; P<0.001). Additionally, as the
ﬁbrosis progressed to high levels seen in cirrhotic patients
(F4), the HAI signiﬁcantly increased as compared to patients
with mild ﬁbrosis (F3; P<0.05).
In Figures 1(a) and 1(b), in the upper panel, the ALT
values were plotted versus the HAI. As can be seen, the
level of ALT was higher when compared to the normal
level. However, the ALT was not signiﬁcantly diﬀerent in
ALD patients or HCV patients in spite of the diﬀerent HAI
levels. Notably, there was a signiﬁcant increase in TNF-α
levels as the HAI increased (Figure 1(a) (HCV patients) and
Figure 1(b) (ALD patients)). Moreover, the TNF-α levels
in ALD patients were signiﬁcantly higher (P<0.05) when
compared with TNF-α levels at the same HAI in HCV
infected individuals.
Regardless the presence or absence of HCV-infection
in the ALD patients, there were no signiﬁcant diﬀerences
between the levels of TNF-α. A positive correlation was
found between the degree of inﬂammation and TNF-α levels
(r = 0.90, P<0.001) in all patients. Also, there was a
signiﬁcant increase in the levels of IL-8 and RANTES at
moderate HAI as compared to patients presenting lower
HAI (r = 0.89; P<0.001), followed by a continued
increase in IL-8 levels and more profoundly RANTES
levels (r = 0.92, P<0.001). This pattern was observed
in all ALD, HCV, and ALD-HCV patients. There were
no signiﬁcant diﬀerences between the levels of IL-8 and
RANTES between the 3 types of patients. Finally, the levels
of IL 6 between these individuals did not diﬀer and were
not signiﬁcantly distinct when compared with the level of
HAI.
As seen in the upper panel of Figure 1,A L Tv a l u e sd on o t
diﬀer with increased severity of inﬂammation. In contrast,
as seen in the lower panel of the graph, TNF-α values diﬀer
signiﬁcantlywiththeincreasedseverityofinﬂammation(P<
0.05) up until the moderate inﬂammatory response. ThereInternational Journal of Hepatology 5
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Figure 1: (a) Correlation between the ALT ± SD measured in U/L (upper panel) (triangles) and HAI (columns: minimal, mild, moderate,
and high inﬂammation by histology) in HCV. The lower panel presents the correlation between TNF-α ± SD ((pg/mL) rhomboid) and
histological activity index (HAI-columns) in the same set of patients. (b) Correlation between the ALT (U/L ± SD (triangles)) and HAI
(solid black columns) is presented in the upper panel graph. TNF-α ((pg/mL ± SD) rhomboid) is correlated in the lower panel with HAI
(solid black columns HAI-0, mild, moderate, high) in patients with ALD.
is no signiﬁcant diﬀerence in the levels of TNF -α between
moderate and high inﬂammatory index.
ALT (IU/L) values do not diﬀer with the increased sever-
ity of inﬂammation neither in HCV Figure 1(a), nor in ALD
individuals (Figure 1(b)). On the contrary, TNF-α values
increase signiﬁcantly with the increased severity of inﬂam-
mation (P<0.05) as described by a histologic inﬂammatory
response. Both in HCV and in ALD the TNF-α gradually
increases, paralleling the increase in HAI until the moderate
HAI. There is a signiﬁcant diﬀerence between the levels of
TNF-α in high HAI versus the moderate HAI in patients
with ALD (P<0.05). This is an exclusive feature for the
ALD individuals since in HCV-infected individuals there is
ap l a t e a uo fT N F - α (Figure 1(a)), between the patients with
moderate and high HAI.
Additionally, apoptosis (M-30) increased dramatically
in the moderate and high HAI. When correlating IL-8
and TNF-α levels with HCV genotype, no signiﬁcance was
observed. There was no correlation between the levels of
ALT and AST with the severity of inﬂammation. There was
a signiﬁcant increase in the level of FAS-L when comparing
patientswithmildHAItothosewithminimalHAI(r = 0.80,
P<0.05).ThelevelofFAS-Lwasmaintainedinpatientswith
moderate HAI, whereas in patients with high HAI a major
increase was seen (P<0.001). Also in ALD-HCV signiﬁcant
increaseinFASlevelswasobservedinpatientswithmoderate
HAI as compared to those with minimal and mild HAI
(r = 0.78, P<0.05). This level was maintained in patients
with high HAI. The same pattern was seen with M-30.
A good correlation was observed between the apoptosome
levels and TNF-α in patients presenting the same degree of
inﬂammation (r = 0.82).
In patients with higher HAI, the levels of apoptosis
and proinﬂammatory cytokines were signiﬁcantly higher
(P<0.001) in patients with ALD when compared with
patients with HCV.
T h el e v e l so fT G F - β increased with the severity of liver
ﬁbrosis in HCV (Figure 2). The patients with ALD and HCV
h a dc o m p a r a b l el e v e l so fT G F - β in the stages of ﬁbrosis F2-
F3. The ALD patients with F4 had levels of TGF-β two times
as high as the patients with HCV. There is no statistical
diﬀerence between the TGF-β levels of in HCV and ALD
patients at F0–F3. At the highest ﬁbrosis level (F4) there is
a statistical diﬀerence (P<0.05) in TGFβ between HCV and
ALD patients.
Hyaluronic acid is a glycosaminoglycan synthesized by
HSCs. HA is eliminated from the circulation by sinusoidal
endothelial cells. In our patients HA levels followed the same
pattern as TGF-β in HCV, increasing signiﬁcantly from 54 ±
16 (ng/mL) (F0-1) to 122 ± 32 (F2) (P<0.05), 207 ±
45 (F3) (P<0.05); 567 ± 85 (F4) (P<0.05). In ALD
patients,thelevelsofHA(ng/mL)alsoincreasedsigniﬁcantly6 International Journal of Hepatology
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Figure 2: Correlation between the levels of TGF-β (ng/mL) in patients with HCV (triangle) and ALD (circle) and ﬁbrosis score (solid black
columns: ﬁbrosis 0-1 (F0-1); ﬁbrosis 2 (F2), ﬁbrosis 3 (F3), cirrhosis (F4)).
versus the previous ﬁbrosis stage 82±16 (F2), 128±25 (F3)
(P<0.05); 497 ± 53 (F4) (P<0.001). No statistically
signiﬁcant diﬀerence in HA was observed between the HCV-
ALD patients and the patients with non-HCV-infected ALD.
Theirvalueswere 65±35 (F2); 120±44 (F3); 360±125 (F4).
In HCV-infected individuals, it is important to observe
the increase of TIMP1 values (ng/mL) (F0-1) 65 ±
12 to 126 ± 12 (F2); 147 ± 45 (F3); 672 ± 58 (F4) (P<
0.001 versus the previous ﬁbrosis stages). In ALD subjects,
the TIMP1 values increased from 105 ± 65 (F2), 205 ±
45 (F3), 872 ± 83 (F4) (P<0.001 versus the previous
ﬁbrosis stages). The levels of TIMP1 (ng/mL) in ALD-HCV
individuals were signiﬁcantly diﬀerent when compared with
HCV individuals at the same HAI (P<0.001) but not
signiﬁcantly diﬀerent from the ALD patients.
Patients with moderate ﬁbrosis presented a dramatic
increase in the HAI as compared to those with mild ﬁbrosis
(P<0.001). In addition, as the ﬁbrosis progressed to
higher levels in the cirrhotic patients, the HAI signiﬁcantly
increased as compared to patients with moderate ﬁbrosis
(P<0.05). The levels of apoptosome (M30) were within
the normal ranges in all patients that presented minimal
inﬂammation. This level was maintained in patients with
moderate HAI. There is a sequential increase in apoptosome
in ALD patients. However, major increase was seen in ALD
patients (P<0.001) versus the moderate HAI. Additionally,
in HCV individuals, a signiﬁcant increase of M30 was
observed (P<0.05). The same pattern was seen in the
levels of M30 in ALD-HCV (P<0.05) increased versus the
moderate HAI.
4. Discussion
The pattern of alcohol consumption is expressed and regu-
lated diﬀerently in diverse geographical regions. Considering
the fact that our population was recruited from Europe and
North America we deﬁned high risk drinking on the average
80g alcohol intake/day.
Over the past ﬁfteen years our laboratory has been focus-
ing on the alterations of the cytokine network in patients
with HCV. We have reported a correlation between TNFα-
as a mediator of inﬂammation and the degree of HAI.
In addition, in our previous studies with noncirrhotics,
we have established that TGFβ- levels reﬂect the histology
ﬁbrosis score [9]. Thus, measuring TNFα-and TGFβ-levels
and correlating them with HAI and ﬁbrosis scores should
bring vital information in assessing and monitoring the
natural history of the disease in patients with HCV. In the
present study we aimed to evaluate the cytokine-chemokine
network in ALD in the presence or absence of HCV
infection. Moreover, we aimed to correlate serum cytokine
and chemokine levels, with the severity of the disease and
to compare the same parameters in ALD patients in the
presence of absence of HCV infection.
Liver ﬁbrosis, regardless of its cause, is characterized
by excess deposition of collagens and ECM proteins in the
parenchyma [26]. The accumulation of interstitial collagens
and ECM proteins results from an imbalance between their
production and degradation by the MMPs. Fibrosis is now
increasingly used as an end point for clinical trials in liver
disease, as stated by the international ﬁbrosis group [53, 54].
The tissue inhibitors of metalloproteinases designated
TIMP-1, TIMP-2, and TIMP-3 regulate the extracellular
activity of their MMPs, which become activated when
released from the cells. TIMPs overexpression correlates
with decreased activity of ECM removing MMPs. Current
evidence indicates that TIMP-1 is the most important
endogenous inhibitor of interstitial collagenase, whereas
TIMP-2isparticularlyimportantintheinhibitionofMMP-2
[55, 56].
TIMP has also emerged as a molecule with dual action.
It inhibits the activity of MMPs and prevents stellate cells
apoptosis [57].
Another component of the ECM is HA, synthesized by
HSCs and eliminated from the circulation by sinusoidal
endothelial cells equipped with a speciﬁc receptor [58–60].International Journal of Hepatology 7
Levels of this ECM protein and other parameters of liver
damage have been proposed to assess the progression of
ﬁbrosisinALD[61,62],aswellasinpatientswithHCV[63].
Therefore the importance of the present work lies in deﬁning
these biomarkers and their role in ALD.
An additional aim of the present study was to evaluate
several markers of ﬁbrosis in a cohort of subjects with a
primary etiology HCV and ALD in the presence or absence
of HCV infection. The overall goal of this paper was to
analyze in HCV and ALD possible markers of inﬂammation
and ﬁbrosis with focus on the ones that correlate best
with the morphologic grade of inﬂammation and ﬁbrosis.
Moreover, special focus has been placed on three markers
(TGF-β, TIMP1, and HA). Other scientists [64–66] also
aimed at establishing tools needed to facilitate diagnosis
and appropriate treatment by using circulating markers
to replace some of the repeated liver biopsies currently
required in the management of many patients with liver
disease.
We report here for the ﬁrst time detailed analyses of
markers of liver inﬂammation and ﬁbrosis in a subgroup of
HCV and alcoholic patients whose liver biopsy was available.
Although the liver biopsy has limitations, the gold standard
of determining and scoring ﬁbrosis is its histological assess-
ment. [67]. Accordingly, a number of circulating markers of
hepatic inﬂammation and ﬁbrogenesis have been proposed
as an alternative to this procedure. Therefore, in addition
to morphologic stages of ﬁbrosis, serum markers of ﬁbrosis
have also been considered to predict the vulnerability for
the future development and progression of the ﬁbrosis. In
chronic HCV patients the combination of several tests in
addition to a liver biopsy improved the diagnostic scores
[68].Inaddition,theconceptof“rateofﬁbrosisprogression”
has been the search of noninvasive surrogate measures of
liver ﬁbrosis [69]. In ALD, Lieber’s team has shown that
chronic alcohol consumption may aﬀect the levels of some
of these ﬁbrosis markers [70–72]. In addition, the role
of nutrition in ALD had been emphasized [73]. In view
of the present work, we consider promising candidates as
noninvasive ﬁbrosis markers: TIMP1, HA, TGF-β.H o w e v e r ,
the greatest clinical usefulness of this test resided in its ability
to exclude cirrhosis. Better predictors of inﬂammation and
ﬁbrosis can be obtained by combining panels of noninvasive
biomarkers in which the accuracy has been analyzed by
a series of algorithms [74, 75]. A combination of new
speciﬁc biomarkers like the ones we described in this
paper with the well-established laboratory changes such
as AST/ALT ratio [76] might help in distinguishing the
etiology of hepatitis. Studies demonstrated that the presence
of HCV and drinking habits are cofactors of risk for alcohol-
induced liver damage [77]. Moreover, practice guidelines in
treating alcoholic liver disease recognized the importance
of biomarkers in identifying the seriousness of the damage
[78, 79]. In addition, the genetic polymorphism in ALD
was evaluated [80]. In a genome-wide association study
performed in 61089 individuals, there were identiﬁed loci
associated with high plasma liver enzyme in individuals with
liver disease. Genes of inﬂammation and immunity (CD276,
CDH6, GCKR, HNF1A, HPR, ITGA1, RORA, and STAT4)
have been shown to be expressed in liver disease patients
[81].
Our study is important, therefore, as it examines the
correlation between liver inﬂammation and serum inﬂam-
matory markers. Serum biomarkers play a substantial role in
identifying and scoring the severity of liver injury induced by
alcohol and its comorbidity with HCV. These ﬁndings need
to be further investigated in patient samples with biopsy-
based assessment of inﬂammation, apoptosis, and ﬁbrosis as
we evaluate in the present cohort.
Since 98% of the entire patient population, originat-
ing from Canada, France, and Israel, was Caucasian, our
study lacked diversity. Though limiting upon ﬁrst glance,
this aspect can actually be useful in that this population
might represent a more homogeneous group regarding their
genetic, immune, and environmental setting. This point
was clearly demonstrated also by the recent study that
investigated the role of Genotype PNPLA3 rs738409(GG)
which is associated with alcoholic liver cirrhosis in alcoholic
Caucasians of German ancestry [82]. In addition, excellent
correlation was found between TGF-β and procollagen IIIN-
peptide (PIIINP) and peptide in patients with alcoholic liver
disease [83]. New approaches using transient elastography
(Fibroscan) may add additional information to evaluate the
degree of ﬁbrosis in hepatitis C and alcohol patients [84, 85].
In summary, all of the inﬂammatory biomarkers were
elevated both in ALD and in HCV, but some of the
biomarkers that were eﬀective for HCV did not perform
as well, in a subgroup with alcoholic ﬁbrosis as primary
etiology. It should be noted that these results are based on a
relatively small cohort of ALD when compared with the very
large cohort of HCV.
Many individual clinical and laboratory features, along
withspeciﬁchistologicalcharacteristics,havealsobeentested
as measures of disease prognosis.
Cytokines play a speciﬁc role in determining the ALD
and HCV progression of liver disease. There is signiﬁcant
imbalance in cytokine milieu that leads to the impairment of
the healing process in both ALD and HCV. This paper brings
evidence suggesting that dysregulated cytokines, including
TNF-α and downstream cytokines, play a pivotal role in
the pathophysiology of ALD, HCV, and their comorbidity.
Environmental factors such as the continued use of heavy
alcohol can accelerate the progression of ALD disease by
activating HSC and enhancing the proﬁbrinogenic cytokine
expression in the liver. However, the progression of ﬁbrosis
is highly variable, with some individuals progressing rapidly
over time whereas other individuals have stable liver disease.
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